Australian Clinical Labs Limited
Australian Clinical Labs Limited (ACL.AX) Stock Competitors & Peer Comparison
See (ACL.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ACL.AX | A$2.71 | -1.81% | 528.3M | 18.07 | A$0.15 | +4.61% |
| SHL.AX | A$27.34 | -0.98% | 13.5B | 23.98 | A$1.14 | +3.91% |
| IDX.AX | A$2.68 | +0.37% | 997.5M | 134.00 | A$0.02 | +2.16% |
| HLS.AX | A$0.76 | -1.95% | 548.2M | -0.79 | -A$0.96 | +84.07% |
| MVF.AX | A$0.80 | -0.63% | 309.8M | -79.50 | -A$0.01 | +6.42% |
| GSS.AX | A$0.34 | +3.03% | 77.2M | -3.40 | -A$0.10 | N/A |
| PEB.AX | A$0.09 | +0.00% | 69M | -2.83 | -A$0.03 | N/A |
| LDX.AX | A$0.08 | +10.96% | 60.6M | -8.10 | -A$0.01 | N/A |
| MAP.AX | A$0.09 | -3.26% | 45.8M | -2.97 | -A$0.03 | N/A |
| IIQ.AX | A$0.40 | +2.60% | 44.1M | -5.64 | -A$0.07 | N/A |
Stock Comparison
ACL.AX vs SHL.AX Comparison August 2025
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 528.3M. In comparison, SHL.AX has a market cap of 13.5B. Regarding current trading prices, ACL.AX is priced at A$2.71, while SHL.AX trades at A$27.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.07, whereas SHL.AX's P/E ratio is 23.98. In terms of profitability, ACL.AX's ROE is +0.18%, compared to SHL.AX's ROE of +0.07%. Regarding short-term risk, ACL.AX is more volatile compared to SHL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for ACL.AX.Check SHL.AX's competition here
ACL.AX vs IDX.AX Comparison August 2025
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 528.3M. In comparison, IDX.AX has a market cap of 997.5M. Regarding current trading prices, ACL.AX is priced at A$2.71, while IDX.AX trades at A$2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.07, whereas IDX.AX's P/E ratio is 134.00. In terms of profitability, ACL.AX's ROE is +0.18%, compared to IDX.AX's ROE of +0.01%. Regarding short-term risk, ACL.AX is more volatile compared to IDX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for ACL.AX.Check IDX.AX's competition here
ACL.AX vs HLS.AX Comparison August 2025
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 528.3M. In comparison, HLS.AX has a market cap of 548.2M. Regarding current trading prices, ACL.AX is priced at A$2.71, while HLS.AX trades at A$0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.07, whereas HLS.AX's P/E ratio is -0.79. In terms of profitability, ACL.AX's ROE is +0.18%, compared to HLS.AX's ROE of -0.02%. Regarding short-term risk, ACL.AX is less volatile compared to HLS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for ACL.AX.Check HLS.AX's competition here
ACL.AX vs MVF.AX Comparison August 2025
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 528.3M. In comparison, MVF.AX has a market cap of 309.8M. Regarding current trading prices, ACL.AX is priced at A$2.71, while MVF.AX trades at A$0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.07, whereas MVF.AX's P/E ratio is -79.50. In terms of profitability, ACL.AX's ROE is +0.18%, compared to MVF.AX's ROE of -0.01%. Regarding short-term risk, ACL.AX is more volatile compared to MVF.AX. This indicates potentially higher risk in terms of short-term price fluctuations for ACL.AX.Check MVF.AX's competition here
ACL.AX vs GSS.AX Comparison August 2025
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 528.3M. In comparison, GSS.AX has a market cap of 77.2M. Regarding current trading prices, ACL.AX is priced at A$2.71, while GSS.AX trades at A$0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.07, whereas GSS.AX's P/E ratio is -3.40. In terms of profitability, ACL.AX's ROE is +0.18%, compared to GSS.AX's ROE of -0.39%. Regarding short-term risk, ACL.AX is less volatile compared to GSS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for ACL.AX.Check GSS.AX's competition here
ACL.AX vs PEB.AX Comparison August 2025
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 528.3M. In comparison, PEB.AX has a market cap of 69M. Regarding current trading prices, ACL.AX is priced at A$2.71, while PEB.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.07, whereas PEB.AX's P/E ratio is -2.83. In terms of profitability, ACL.AX's ROE is +0.18%, compared to PEB.AX's ROE of -0.86%. Regarding short-term risk, ACL.AX is less volatile compared to PEB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for ACL.AX.Check PEB.AX's competition here
ACL.AX vs LDX.AX Comparison August 2025
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 528.3M. In comparison, LDX.AX has a market cap of 60.6M. Regarding current trading prices, ACL.AX is priced at A$2.71, while LDX.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.07, whereas LDX.AX's P/E ratio is -8.10. In terms of profitability, ACL.AX's ROE is +0.18%, compared to LDX.AX's ROE of -0.59%. Regarding short-term risk, ACL.AX is less volatile compared to LDX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for ACL.AX.Check LDX.AX's competition here
ACL.AX vs MAP.AX Comparison August 2025
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 528.3M. In comparison, MAP.AX has a market cap of 45.8M. Regarding current trading prices, ACL.AX is priced at A$2.71, while MAP.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.07, whereas MAP.AX's P/E ratio is -2.97. In terms of profitability, ACL.AX's ROE is +0.18%, compared to MAP.AX's ROE of -0.48%. Regarding short-term risk, ACL.AX is less volatile compared to MAP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for ACL.AX.Check MAP.AX's competition here
ACL.AX vs IIQ.AX Comparison August 2025
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 528.3M. In comparison, IIQ.AX has a market cap of 44.1M. Regarding current trading prices, ACL.AX is priced at A$2.71, while IIQ.AX trades at A$0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.07, whereas IIQ.AX's P/E ratio is -5.64. In terms of profitability, ACL.AX's ROE is +0.18%, compared to IIQ.AX's ROE of -0.36%. Regarding short-term risk, ACL.AX is less volatile compared to IIQ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for ACL.AX.Check IIQ.AX's competition here
ACL.AX vs CTE.AX Comparison August 2025
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 528.3M. In comparison, CTE.AX has a market cap of 36.6M. Regarding current trading prices, ACL.AX is priced at A$2.71, while CTE.AX trades at A$0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.07, whereas CTE.AX's P/E ratio is 18.75. In terms of profitability, ACL.AX's ROE is +0.18%, compared to CTE.AX's ROE of +1.33%. Regarding short-term risk, ACL.AX is more volatile compared to CTE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for ACL.AX.Check CTE.AX's competition here
ACL.AX vs BDX.AX Comparison August 2025
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 528.3M. In comparison, BDX.AX has a market cap of 20.5M. Regarding current trading prices, ACL.AX is priced at A$2.71, while BDX.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.07, whereas BDX.AX's P/E ratio is -1.87. In terms of profitability, ACL.AX's ROE is +0.18%, compared to BDX.AX's ROE of -0.90%. Regarding short-term risk, ACL.AX is more volatile compared to BDX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for ACL.AX.Check BDX.AX's competition here
ACL.AX vs RHY.AX Comparison August 2025
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 528.3M. In comparison, RHY.AX has a market cap of 17.4M. Regarding current trading prices, ACL.AX is priced at A$2.71, while RHY.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.07, whereas RHY.AX's P/E ratio is -6.00. In terms of profitability, ACL.AX's ROE is +0.18%, compared to RHY.AX's ROE of -0.76%. Regarding short-term risk, ACL.AX is less volatile compared to RHY.AX. This indicates potentially lower risk in terms of short-term price fluctuations for ACL.AX.Check RHY.AX's competition here
ACL.AX vs GTG.AX Comparison August 2025
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 528.3M. In comparison, GTG.AX has a market cap of 5.7M. Regarding current trading prices, ACL.AX is priced at A$2.71, while GTG.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.07, whereas GTG.AX's P/E ratio is -3.90. In terms of profitability, ACL.AX's ROE is +0.18%, compared to GTG.AX's ROE of -3.62%. Regarding short-term risk, ACL.AX is more volatile compared to GTG.AX. This indicates potentially higher risk in terms of short-term price fluctuations for ACL.AX.Check GTG.AX's competition here
ACL.AX vs IBX.AX Comparison August 2025
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 528.3M. In comparison, IBX.AX has a market cap of 3M. Regarding current trading prices, ACL.AX is priced at A$2.71, while IBX.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.07, whereas IBX.AX's P/E ratio is -0.30. In terms of profitability, ACL.AX's ROE is +0.18%, compared to IBX.AX's ROE of +0.55%. Regarding short-term risk, ACL.AX is less volatile compared to IBX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for ACL.AX.Check IBX.AX's competition here
ACL.AX vs WFL.AX Comparison August 2025
ACL.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACL.AX stands at 528.3M. In comparison, WFL.AX has a market cap of 1.5M. Regarding current trading prices, ACL.AX is priced at A$2.71, while WFL.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACL.AX currently has a P/E ratio of 18.07, whereas WFL.AX's P/E ratio is -0.10. In terms of profitability, ACL.AX's ROE is +0.18%, compared to WFL.AX's ROE of +11.65%. Regarding short-term risk, ACL.AX is more volatile compared to WFL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for ACL.AX.Check WFL.AX's competition here